Literature DB >> 24350076

Insulin Resistance and Atherosclerosis: Is it Time to Measure HOMA-IR to Predict Coronary Artery Disease?

Lakshmi Kannan1, Arthur Chernoff2.   

Abstract

Entities:  

Year:  2013        PMID: 24350076      PMCID: PMC3842705          DOI: 10.4103/1947-2714.120800

Source DB:  PubMed          Journal:  N Am J Med Sci        ISSN: 1947-2714


× No keyword cloud information.
Atherothrombotic cardiovascular disease (CVD) is the leading cause of death worldwide, despite remarkable advances in detection and management. The American Heart Association estimates that by 2030 at least 40% of the US population will have some form of CVD. Well-established modifiable risk factors include dyslipidemia, hypertension, obesity, diabetes mellitus, the metabolic syndrome and physical inactivity. Of these, insulin resistance (IR) is common to metabolic syndrome, diabetes mellitus and obesity. In this issue of North American Journal of Medical Sciences, Srinivasan et al., have provided data that relates the severity of insulin resistance to the severity of coronary artery disease.[1] Insulin resistance is mediated by the interplay of a person's genetic substrate and acquired pathophysiologic insults. Molecular studies have established that insulin resistance has a key role in every stage of atherosclerosis from the initiation and progression of early atherosclerosis to the formation of clinically significant plaques. In the early stages, insulin resistance appears to affect various molecular pathways at the cellular level in endothelial cells, macrophages and vascular smooth muscle cells.[2] Despite a wealth of data linking insulin resistance and atherosclerosis at the molecular level, the relation between the two in clinical settings has remained uncertain. A multi-center study reported an association between IR and multi-vessel coronary artery disease (CAD) in non-diabetic post-myocardial infarction survivors that was independent of other metabolic risk factors.[3] Another cross-sectional study from Europe reported that IR mediates subclinical atherosclerosis by increasing abdominal adiposity.[4] In an analysis of NHANES population data, we were able to demonstrate that IR was a greater risk for CVD than diabetes itself and that IR was associated with a higher risk of CVD in non-diabetics than in diabetics.[5] In the current study, the authors have taken this a step further and examined the relationship between insulin resistance and the severity of clinically apparent coronary artery disease. HOMA-IR was used to indicate insulin resistance while the Gensini score denoted CAD severity. They found statistically significant correlations between the HOMA-IR and the Gensini scores in their population. Interestingly in their multivariate analysis they did not find statistically significant associations with other known risk factors for CAD. In this way the authors have demonstrated a significant correlation between the insulin resistance and CAD. Though this positive correlation was small in statistical terms, it is a significant addition to the growing knowledge of the key role of insulin resistance in atherosclerosis. They conclude that they might be able to predict severity of CAD by measuring HOMA-IR. This is in contrast to other studies that have questioned the relative contribution of IR to clinically significant atherosclerotic disease. For example, a multiethnic study concluded that determination of the HOMA-IR is unlikely to improve detection of sub-clinical atherosclerosis.[6] The question then remains: Are we approaching primary prevention of coronary artery disease correctly by just screening for and treating diabetes mellitus and hyperlipidemia, while ignoring insulin resistance?
  6 in total

1.  Abdominal adiposity largely explains associations between insulin resistance, hyperglycemia and subclinical atherosclerosis: the NEO study.

Authors:  Karin B Gast; Johannes W A Smit; Martin den Heijer; Saskia Middeldorp; Ralph C A Rippe; Saskia le Cessie; Eelco J P de Koning; J W Jukema; Ton J Rabelink; Albert de Roos; Frits R Rosendaal; Renée de Mutsert
Journal:  Atherosclerosis       Date:  2013-06-01       Impact factor: 5.162

2.  Correlation of severity of coronary artery disease with insulin resistance.

Authors:  Mukund P Srinivasan; Padmanabh K Kamath; Poornima A Manjrekar; B Unnikrishnan; Aishwarya Ullal; Mohammed Faheem Kotekar; Chakrapani Mahabala
Journal:  N Am J Med Sci       Date:  2013-10

Review 3.  Insulin resistance, hyperglycemia, and atherosclerosis.

Authors:  Karin E Bornfeldt; Ira Tabas
Journal:  Cell Metab       Date:  2011-11-02       Impact factor: 27.287

4.  The risk for coronary heart disease according to insulin resistance with and without type 2 diabetes.

Authors:  Jongoh Kim; Young Kwang Chae; Arthur Chernoff
Journal:  Endocr Res       Date:  2013-02-20       Impact factor: 1.720

5.  Insulin resistance is associated with significant clinical atherosclerosis in nondiabetic patients with acute myocardial infarction.

Authors:  Wassef Karrowni; Yan Li; Philip G Jones; Sharon Cresci; Mouin S Abdallah; David E Lanfear; Thomas M Maddox; Darren K McGuire; John A Spertus; Phillip A Horwitz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-07-18       Impact factor: 8.311

6.  Insulin resistance, metabolic syndrome, and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Alain G Bertoni; Nathan D Wong; Steven Shea; Shuangge Ma; Kiang Liu; Srikanthan Preethi; David R Jacobs; Colin Wu; Mohammed F Saad; Moyses Szklo
Journal:  Diabetes Care       Date:  2007-08-17       Impact factor: 19.112

  6 in total
  2 in total

1.  Does homeostasis model assessment of insulin resistance have a predictive value for post-coronary artery bypass grafting surgery outcomes?

Authors:  Ebuzer Aydin; Mehmet Ozkokeli
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Jul-Sep

Review 2.  New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis.

Authors:  Ting Yuan; Ting Yang; Huan Chen; Danli Fu; Yangyang Hu; Jing Wang; Qing Yuan; Hong Yu; Wenfeng Xu; Xiang Xie
Journal:  Redox Biol       Date:  2018-10-19       Impact factor: 11.799

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.